BerandaADAP • NASDAQ
add
Adaptimmune Therapeutics PLC - ADR
Tutup sebelumnya
$0,59
Rentang hari
$0,57 - $0,61
Rentang tahun
$0,53 - $2,05
Kapitalisasi pasar
147,97 jt USD
Volume Rata-Rata
2,24 jt
Bursa utama
NASDAQ
Berita pasar
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
| (USD) | Sep 2024info | Perubahan Y/Y |
|---|---|---|
Pendapatan | 40,90 jt | 458,83% |
Biaya operasional | 21,28 jt | 31,63% |
Laba bersih | -17,62 jt | 61,37% |
Margin laba bersih | -43,07 | 93,09% |
Penghasilan per saham | -0,01 | 70,15% |
EBITDA | -11,86 jt | 72,88% |
Tarif pajak efektif | -4,95% | — |
Neraca
Total aset
Total liabilitas
| (USD) | Sep 2024info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 186,09 jt | 15,06% |
Total aset | 317,44 jt | 7,01% |
Total liabilitas | 237,45 jt | 13,88% |
Total ekuitas | 79,99 jt | — |
Saham yang beredar | 255,88 jt | — |
Harga terhadap nilai buku | 1,91 | — |
Tingkat pengembalian aset | -11,48% | — |
Tingkat pengembalian modal | -24,62% | — |
Arus Kas
Perubahan kas bersih
| (USD) | Sep 2024info | Perubahan Y/Y |
|---|---|---|
Laba bersih | -17,62 jt | 61,37% |
Kas dari operasi | -54,45 jt | -20,58% |
Kas dari investasi | -66,02 jt | -215,20% |
Kas dari pembiayaan | 25,00 jt | 4.094,80% |
Perubahan kas bersih | -95,25 jt | -840,01% |
Arus kas bebas | -41,07 jt | -62,70% |
Tentang
Adaptimmune is a biopharmaceutical company that develops T cell therapies against cancer. The company was founded in 2008 in the UK with links to both Oxford University and the University of Pennsylvania. It has headquarters in Philadelphia and Milton Park. In August 2024, the US Food and Drug Administration granted accelerated approval to Adaptimmune's Tecelra, a therapy against a rare form of cancer. Tecelra is the first T cell therapy to be approved for use against a solid tumor. Wikipedia
Didirikan
2008
Situs
Karyawan
449
